Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata
Article Date
October 13, 2023
This article is featured on another website.
Go to article
July 13, 2026
HiRO to Attend the 2026 Australia & New Zealand Site Solutions Summit
HiRO is heading to Melbourne this July for the ANZ Site Solutions Summit. The event…
July 13, 2026
HiRO to Attend the 2026 Australia & New Zealand Site Solutions Summit
HiRO is heading to Melbourne this July for the ANZ Site Solutions Summit. The event…
June 1, 2026
Chime Biologics and Daewoong Pharmaceutical Enter Strategic Partnership to Advance Dupilumab Biosimilar Development and Commercialization in Global Markets
June 1, 2026